Interestingly, it was suggested that BMPRII inhibits activin signalling via ALK2 because knocking down BMPR2 by siRNA lead to enhanced ActA-phospho-SMAD1/5 signalling via ALK2 in multiple myeloma cells [88]. The gene discussed is ACVR1; the disease is plasma cell myeloma.